Novocure (NVCR) Tops Q4 EPS by 7c

Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $133.78 million versus the consensus estimate of $129.31 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Artiva Biotherapeutics, Inc. (ARTV) Misses Q2 EPS by 63c
• Evommune, Inc. (EVMN) Misses Q2 EPS by 20c